Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib in PIK3CA-mutated metastatic colorectal cancer
NCT07323576Phase 2Withdrawn
- Sponsor
- Roche
- Start
- Feb 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of inavolisib in colorectal cancer (metastatic) (mCRC), sponsored by Roche. Planned start Feb 2026; status: withdrawn.
02
Drugs
inavolisib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT07323576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07323576.